28 November 2024,   12:39
more
Moderna’s COVID-19 vaccine shows promise against Delta variant in lab study

Moderna Inc’s (MRNA.O) COVID-19 vaccine showed promise against the Delta variant first identified in India in a lab study, with a modest decrease in response compared to the original strain, the drugmaker said, writes Reuters.

The study was conducted on blood serum from eight participants obtained one week after they received the second dose of the vaccine in an early-stage trial.

Vaccination produced antibodies against all variants, including additional versions of the Beta variant first identified in South Africa and three lineage variants first identified in India, including the Kappa and the Delta variants.

The study was conducted on blood serum from eight participants obtained one week after they received the second dose of the vaccine in an early-stage trial.

Vaccination produced antibodies against all variants, including additional versions of the Beta variant first identified in South Africa and three lineage variants first identified in India, including the Kappa and the Delta variants.

MORE HEADLINES